The effect of hyperglycemia and oxidative stress on the development and progress of vascular complications in type 2 diabetes

Journal of Medical Biochemistry

Volumn 28, Issue 2, 2009, Pages 63-71

  Čolak, Emina ^a   Majkić Singh, Nada ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Diabetes mellitus; Free radicals; Hyperglycemia; Oxidative stress; Vascular complications

Indexed keywords

AMINOKETONE; APOLIPOPROTEIN B; FREE RADICAL; GLUTATHIONE REDUCTASE; GROWTH FACTOR; HEXOSAMINE; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; POLYOL; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONFORMATION; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME GLYCOSYLATION; HYPERGLYCEMIA; INFLAMMATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; TISSUE INJURY; VASCULAR TISSUE;

EID: 65249166998     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-009-0006-y     Document Type: Article

References (78)

1. Giugliano D, Ceriello A. Oxidative stress and diabetic vascular complications. Diabetes 1996; 19: 257-67.
2. Bonnefont-Rousselot D, Bastard J P, Jaudon MC, Delattre J. Consequences of the diabetic status on the oxidant-antioxidant balance. Diabetes & Metabolism 2000; 26: 163-74.
3. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovascular Diabetology 2002; 1: 1-10.
4. Pavlović DD, Dortević B V, Kocić MG. Ćelijska signalna transdukcija-modulacija slobodnim radikalima. Jugo -slov Med Biohem 2002; 21: 69-84.
5. Baynes J W, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
6. Wolff S P. Diabetes mellitus and free radicals. Free ra di -cals, transition metals and oxidative stress in the aetio -logy of diabetes mellitus and complications. Br Med Bull 1993; 49: 6425-32.
7. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-42
8. Tuiyama Y, Griendling KK. Reactive oxygen species in the vasculature. Hypertension 2003; 43: 10758-64.
9. Čolak E, Dimitrijević-Srećković V, Dordević PB, Stan -kovć S, Majkić-Singh N, Lalić K, et al. The influence of type and duration of cardiovascular complications on anti oxidative parameter values in type 2 diabetic patients. Journal of Medical Biochemistry 2007; 1: 10-7.
10. Čolak E, Majkić-Singh N, Stanković S, Srećković- Dimitrijević V, Dordević PB, Lalić K, et al. The effect of hy -perglycemia on the values of antioxidative parameters in type 2 diabetic patients with cardiovascular compli -cations. Jugoslov Med Biohem 2006; 25: 173-9.
11. Brownlee M. The pathobiology of diabetic complica -tions. A unifying mechanism. Diabetes 2005; 54: 1615-25.
12. Maillard L. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. C R Acad Sci (Paris) 1912; 154: 66-8.
13. Wautier JL, Schmidt AM. Protein glycation - a firm link to endothelial dysfunction. Circulation Research 2004; 95: 233-8.
14. Brownlee M, Cerami A, Vlassara H. Advanced glyco -sylation end products in tissue and the biochemical ba -sis of diabetic complication. N Engl J Med 1988; 318: 1315-21.
15. Čolak E. New markers of oxidative damage to macro -molecules. Journal of Medical Biochemistry 2008; 27 (1): 1-16.
16. Berg TJ, Clausen J T, Torjesen PA, Dohl-Jorgensen K, Bangstad HJ, Hanssen K F. The advanced glycation end product N epsilon-(carboxymethyl) lysine is increased in serum from children and adolescents with type 1 dia -betes. Diabetes Care 1998; 21: 1997-2002.
17. Chellan P, Nagaraj RH. Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. Arch Biochem Biophys 1999; 368: 98-104.
18. Lederer MO, Klaiber RG. Cross-linking of proteins by Maillard processes: characterization and detection of lysine-arginine cross-links derived from glyoxal and methylglyoxal. Bioorg Med Chem 1999; 7: 24995-7.
19. Thornalley PJ, Langborn A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the gly -cation of proteins by glucose. Biochem J 1999; 344: 109-16.
20. Oya T, Hattori N, Mizuno Y, Miyata S, Maeda S, Osawa T, et al. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methyl glyo x -al-arginine adducts. J Biol Chem 1999; 274: 18492 -502.
21. Paul RG, Bailey AJ. The effect of advanced glycation end product formation upon cell-matrix interactions. Int J Biochem Cell Biol 1999; 31: 653-60.
22. Thornalley PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: invol ve -ment in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interact 1998; 111: 137-51.
23. Ranganathan S, Ciaccio PJ, Walsh ES, Tew KD. Geno -mic sequence of human glyoxalase-I: analysis of pro -moter activity and its regulation. Gene 1999; 240: 149- 55.
24. Abordo EA, Minhas HS, Thornalley PJ. Accumulation of alpha-oxoaldehydes during oxidative stress: a role of cytotoxicity. Biochem Pharmacol 1999; 58: 641-8.
25. Ahmed N, Thornalley PJ. Quantitative screening of protein biomarkers of early glycation, advanced gly ca -tion, oxidation and nitrozation in cellular and extra -cellular proteins by tandem mass spectrometry multiple reaction monitoring. Biochem Soc Trans 2003; 31: 1417-22.
26. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxi -da tion in vivo. Proc Natl Acad Sci USA 1993; 90: 6434-8.
27. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Indentification of the major site of apoli -poprotein B modification by advanced glycosylation end products blocking uptake by the low density lipo -protein receptor. J Biol Chem 1995; 270: 10828-32.
28. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H. Modification of low density lipo -protein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91: 9441-5.
29. Steinbrecher U P, Witztum JL. Glucosylation of low-den -sity lipoprotein to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984; 33: 130-4.
30. Čolak E. Uticaj hiperglikemije na vrednosti antioksi da -tivnih parametara kod dijabetičara tipa 2 sa kardio -vaskularnim komplikacijama. Farmaceutski fakultet Beograd 2005, magistarski rad.
31. Zamaklar M, Lalić K, Rajković N, Trifunović D, Draga -šević M, Popović Lj, et al. Oxidized LDL and other lipids as risk factors for cardiovascular disease in the patients with metabolic syndrome. Jugoslov Med Biohem 2005; 24 (2): 99-106.
32. Klein RL, Laimins M, Lopes-Virella M F. Isolation, cha -racterization, and metabolism of the glycated and non -glycated subfractions of low-density lipoproteins isolated from type 1 diabetic patients and nondiabetic subjects. Diabetes 1995; 44: 1093-8.
33. Picard S, Talussot C, Serusclat A, Ambrosio N, Bert -hezene F. Minimaly oxidized LDL as estimated by a new method increase in plasma of type 2 diabetic patients with atherosclerosis or nephropathy. Diabetes Metab 1996; 22: 25-30.
34. Dimitrijević-Srećković V, Dordević P, Gostiljac D, Čolak E, Srećković B, Popović S, et al. Quinquennial follow-up of prediabetic patients progressing into diabetics. Dia -betes & Vascular Disease Research, 2007;4: Suppl. l, S105.
35. Dimitrijević-Srećković V, Čolak E, Dordević P, Gostiljac D, Srećković B, Popović S, et al. Prothrombogenic factors and reduced antioxiative defense in children and adolescents with pre-metabolic and metabolic syndrome. Clin Chem Lab Med 2007; 45 (9): 1140-4.
36. Jain SK, Mc Vie R, Jaramillo JJ, Chen Y. Hyperke -tonemia (acetoacetate) increases the oxidizability of LDL+VLDL in type 1 diabetic patients. Free Radic Biol Med 1998; 24; 175-81.
37. Leonhardt W, Hanefeld M, Muller G, Hora C, Meissner D, Lattke P et al. Impact of concentration of glycated he moglobin, alpha-tocopherol, copper and manganese on oxidation of low-density lipoprotein in patients with type 1 diabetes, type 2 diabetes and control subjects. Clin Chim Acta 1996; 254: 173-86.
38. Oranje WA, Rondas-Colbers GJ, Swennen GN, Jansen H, Wolffenbuttel BH. Lack of effect on LDL oxidation and antioxidant status after improvement of metabolic control in type 2 diabetes. Diabetes Care 1999; 22: 2083-4.
39. Carantoni M, Abbasi F, Warmerdam F, Klebanov M, Wang PW, Chen YD, et al. Relationship between insulin resistance and partially oxidized LDL particles in healthy, nondiabetic volunteers. Arterioscler Thromb Vasc Biol 1998; 18: 762-7.
40. Lopes-Virella M F, Virella G. Cytokines, modified lipo -proteins and arteriosclerosis in diabetes. Diabetes 1996; 45: S40-S44.
41. Lopes-Virella M F, Virella G, Orchard TJ, Koskinen S, Evans R W, Becker DJ, et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 1999; 90: 165-72.
42. Brett J. Survey of the distribution of a newly charac -terized receptor for advanced glycation end products in tissue. Am J Pathol 1993; 143: 1699-712.
43. Ritthaler U, Deng Y, Zhang Y, Greten J, Abel M, Sido B, et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 1995; 146: 688-94.
44. Schmidt AM, Du Yau Shi, Wautier JL, Stern D. Acti va -tion of receptors for advanced glycation end products. Circulation Research 1999; 84: 489-97.
45. Kilhovd BK, Juntilainen A, Lehto S, Rönnemaa T, Torjensen PA, Birkeland KJ, et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men-a population based 18 years follow-up study. Arterioscler Thromb Vasc Biol 2005; 25 (4): 815-20.
46. Falcone C, Emanuele E, D'Angelo A, Puzzi M P, Belvito C, Cuccia M, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25 (5): 1032-7.
47. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-97.
48. Wautier JL, Wautier M P, Schmidt AM, Anderson GM, Hori O, Zoukourian C, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via specific receptor inducing oxidant stress in the vasculature: a link between sur -face-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 1994; 91: 7742-6.
49. Schmidt AM, Hori O, Chen JX, Li J F, Crandall J, Zhang J, et al. Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cul -tured human endothelial cells in mice. A potential mechanism for the accelerated vasculopathy of dia be -tes. J Clin Invest 1995; 96: 1395-403.
50. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface binding proteins for advanced glycation end products. J Clin Invest 1993; 91: 2155 -68.
51. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlas -sara H. Advanced protein glycosylation induces trans -endothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 1990; 87: 9010-4.
52. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glu -cose-modified proteins: role in normal tissue remodel -ing. Science 1988; 240: 1546-8.
53. Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-spe -cific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992; 90: 439-46.
54. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
55. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70: 138-51.
56. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. Faseb J 1999; 13: 23-30.
57. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 1994; 16: 383-91.
58. Greene DA, Stevens MJ. The sorbitol-osmotic and sor -bitol redox hypotheses. In: Le Roith D, Taylor SI, Olef -sky JM, eds. Diabetes Mellitus. Philadelphia: Lippincott--Raven Publishers 1996.
59. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432-8.
60. Kolni-Litty V, Sauer U, Nerlich A, Lehman R, Schleicher ED. High glucose-induced tranforming growth-factor beta 1 production is mediated by the hexozamine path -way in porcine glomerular mesangial cells. J Clin Invest 1998; 101: 160-9.
61. Wells L, Hart G. O-GlcNAc turns twenty: functional implications for posttranslational modification of nu -clear and cytosolic protein with a sugar. FEBS Lett 2003; 546: 154-8.
62. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh T, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexozamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000; 97: 12222-6.
63. Pressler D, Rudich A, Bashan N. Oxidative stress im -pairs nuclear proteins binding to the insulin responsive element in the GLUT 4 promoter. Diabetologia 2001; 44: 2156-64.
64. Tomkin GH. Diabetic vascular disease and the rising star of protein kinase C. Diabetologia 2001; 44: 657-8.
65. Tomlinson DR. Mitogen-activated protein kinases as glu cose transducers for diabetic complications. Diabe -to logia 1999; 42: 1271-81.
66. Koya D, King GL. Protein kinase C and the develop -ment of diabetic complications. Diabetes 1998; 47: 859-66.
67. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to gly -cemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992; 89: 11059-63.
68. Ikeda Y, Olsen GS, Ziv E, Hansen LL, Busch AK, Han -sen B F, et al. Cellular mechanism of nutritionally in -duced insulin resistance in Psammomys obesus: over -expression of protein kinase C epsilon in skeletal muscle precedes the onset of hyperinsulinemia and hyper -glycemia. Diabetes 2001; 50: 584-92.
69. Nabel E, Shum L, Pompili V, Yang Z-Y, San H, Shu H, et al. Direct transfer of transforming growth factor b1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 1993; 90: 10759-63.
70. Koya D, Jirousek MR, Lin YW, Issii H, Kuboki K, King GL. Characteristics of protein kinase C b isoform acti -vation on gene expression of transforming growth factor b, extracellular matrix components and pros -tanoids in the glomeruli of diabetic rats. J Clin Invest 1997; 100: 115-26.
71. Li P F, Maasch C, Haller H, Dietz R, Von Harsdorf R. Requirement for protein kinase C in reactive oxygen species-induced apoptosis of vascular smooth muscle cells. Circulation 1999; 100: 967-73.
72. Aiello L P, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah S T, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
73. Tomlinson DR. Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabe -tologia 1999; 42: 1271-81.
74. Davis RJ. Transcriptional regulation bay MAP kinases. Mol Reprod Dev 1995; 42: 459-67.
75. Guyton KZ, Liu Y, Gorospe M, XuQ, Holbrook NJ. Acti -vation of mitogen-activated protein kinase by h202. Role in cell survival following oxidant injury. J Biol Chem 1996; 271: 4138-42.
76. English JM, Cobb MH. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 2002; 23: 40-5.
77. Pavlović D, Kocić R, Kocić G, Dordević V, Bjelaković G, Kora}evi} D. Therapeutic effects of vitamin E and C on the serum lipid peroxidation and glycaemia in diabetic subjects. Diabetologia 1992; 35 (Suppl 1): A 201-2.
78. Pavlović D, Bjelaković G. A possibile link between poly -amines and thiol redox signaling pathway in diabetic liver. J Hepatology 2001; 34 (Suppl 1): 94-5.